Viewed together, these data confirm a role for the UHMK1 RNA processing pathway in MAPK pathway inhibitor responses in BRAFV600 melanoma cells both in vitro and in vivo, and demonstrate UHMK1 inactivation is sufficient to delay targeted therapy resistance. This evidence concerns the gene UHMK1 and melanoma.